BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 27411054)

  • 1. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
    Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
    JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
    J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
    Schaberg KB; Novoa RA; Wakelee HA; Kim J; Cheung C; Srinivas S; Kwong BY
    J Cutan Pathol; 2016 Apr; 43(4):339-46. PubMed ID: 26762844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.
    Rivera N; Boada A; Bielsa MI; Fernández-Figueras MT; Carcereny E; Moran MT; Ferrándiz C
    JAMA Dermatol; 2017 Nov; 153(11):1162-1165. PubMed ID: 28700789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
    Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
    J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.
    Sibaud V; Eid C; Belum VR; Combemale P; Barres B; Lamant L; Mourey L; Gomez-Roca C; Estilo CL; Motzer R; Vigarios E; Lacouture ME
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):e464-e469. PubMed ID: 28419570
    [No Abstract]   [Full Text] [Related]  

  • 9. Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
    Chou S; Hwang SJ; Carlos G; Wakade D; Fernandez-Penas P
    Am J Dermatopathol; 2017 Jan; 39(1):23-27. PubMed ID: 28045749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
    Obara K; Masuzawa M; Amoh Y
    J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
    Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
    J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
    Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
    J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.
    Joseph RW; Cappel M; Goedjen B; Gordon M; Kirsch B; Gilstrap C; Bagaria S; Jambusaria-Pahlajani A
    Cancer Immunol Res; 2015 Jan; 3(1):18-22. PubMed ID: 25287118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
    Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
    Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
    Martínez-Doménech Á; García-Legaz Martínez M; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Pérez-Ferriols A
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.
    Shen J; Chang J; Mendenhall M; Cherry G; Goldman JW; Kulkarni RP
    Ther Adv Med Oncol; 2018; 10():1758834017751634. PubMed ID: 29383039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
    Esfahani K; Henderson Berg MH; Zargham H; Billick R; Pehr K; Redpath M; Roshdy O; Miller WH
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-Report of 4 cases.
    Chou S; Zhao C; Hwang SJE; Fernandez-Penas P
    J Cutan Pathol; 2017 Oct; 44(10):851-856. PubMed ID: 28753231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.